Decreased regulatory T‑cell frequency and interleukin‑35 levels in patients with rheumatoid arthritis

Zhang,Xia; Zhang,Xiaolu; Zhuang,Lili; Xu,Cangcang; Li,Tao; Zhang,Guili; Liu,Ying

doi:10.3892/etm.2018.6885

Decreased regulatory T‑cell frequency and interleukin‑35 levels in patients with rheumatoid arthritis

Authors:
- Xia Zhang
- Xiaolu Zhang
- Lili Zhuang
- Cangcang Xu
- Tao Li
- Guili Zhang
- Ying Liu
View Affiliations

Affiliations: Department of Immunology, Hunan Normal University School of Medicine, Changsha, Hunan 410013, P.R. China, Department of Laboratory Medicine, Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China, Reproductive Medicine Center, Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China, Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Hunan Normal University School of Medicine, Changsha, Hunan 410013, P.R. China, Department of Rheumatology, Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China
Published online on: October 19, 2018 https://doi.org/10.3892/etm.2018.6885
Pages: 5366-5372

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Interleukin‑35 (IL‑35) is a newly discovered anti‑inflammatory cytokine predominantly released by regulatory T cells (Tregs) and may serve an important role in the pathogenesis of autoimmune diseases. The levels of IL‑35 and corresponding Treg frequencies in patients with rheumatoid arthritis (RA) have scarcely been reported. The present study aimed to detect serum IL‑35 levels and Treg frequencies in patients with RA, and analyze their association with each other and with indicators of RA. A total of 55 patients with RA, including 37 active‑phase (AP) and 18 chronic‑phase (CP) cases, as well as 20 healthy controls (HC), were recruited. Clinical parameters, including erythrocyte sedimentation rate (ESR), C‑reactive protein (CRP) levels, rheumatoid factor (RF), anti‑cyclic citrullinated peptide (CCP) antibody and 28‑joint disease activity score (DAS28) were assessed. The Treg frequency in peripheral blood (PB) was determined by flow cytometry. IL‑35 mRNA in PB mononuclear cells of the patients with RA was measured by reverse transcription‑quantitative polymerase chain reaction analysis, and IL‑35 levels in the serum were detected by ELISA. The correlations between IL‑35 levels and the abovementioned indexes were analyzed by determining Pearson's correlation coefficient. The results of the present study indicated that the Treg frequency was significantly decreased in patients with RA compared with that in HC. No significant difference in Treg frequency between the AP and CP groups of RA patients was identified. In addition, the serum IL‑35 levels and mRNA expression in RA patients were obviously lower than those in the HC. Of note, the serum IL‑35 levels were negatively correlated with the ESR and DAS28 of patients with RA, while no correlation with CRP, RF or anti‑CCP antibodies was identified. In addition, a significant positive correlation was revealed between serum IL‑35 levels and the Treg frequency. These results suggest that IL‑35 and Tregs have a protective role regarding the development of RA.

View Figures

View References

1	McInnes IB and Schett G: The pathogenesis of rheumatoid arthritis. N Engl J Med. 365:2205–2219. 2011. View Article : Google Scholar : PubMed/NCBI
2	Wing K and Sakaguchi S: Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol. 11:7–13. 2010. View Article : Google Scholar : PubMed/NCBI
3	Zhang H, Guo H, Lu L, Zahorchak AF, Wiseman RW, Raimondi G, Cooper DK, Ezzelarab MB and Thomson AW: Sequential monitoring and stability of ex vivo expanded autologous and nonautologous regulatory T cells following infusion in nonhuman primates. Am J Transplant. 15:1253–1266. 2015. View Article : Google Scholar : PubMed/NCBI
4	Morgan ME, Flierman R, van Duivenvoorde LM, Witteveen HJ, van Ewijk W, van Laar JM, de Vries RR and Toes RE: Effective treatment of collagen induced arthritis by adoptive transfer of CD25+ regulatory T cells. Arthritis Rheum. 52:2212–2221. 2005. View Article : Google Scholar : PubMed/NCBI
5	Nguyen LT, Jacobs J, Mathis D and Benoist C: Where FoxP3-dependent regulatory T cells impinge on the development of inflammatory arthritis. Arthritis Rheum. 56:509–520. 2007. View Article : Google Scholar : PubMed/NCBI
6	Alunno A, Manetti M, Caterbi S, Ibba-Manneschi L, Bistoni O, Bartoloni E, Valentini V, Terenzi R and Gerli R: Altered immunoregulation in rheumatoid arthritis: The role of regulatory T cells and proinflammatory Th17 cells and therapeutic implications. Mediators Inflamm. 2015:7517932015. View Article : Google Scholar : PubMed/NCBI
7	Jiao Z, Wang W, Jia R, Li J, You H, Chen L and Wang Y: Accumulation of FoxP3 expressing CD4+CD25+ T cells with distinct chemokine receptors in synovial fluid of patients with active rheumatoid arthritis. Scand J Rheumatol. 36:428–433. 2007. View Article : Google Scholar : PubMed/NCBI
8	Möttönen M, Heikkinen J, Mustonen L, Isomäki P, Luukkainen R and Lassila O: CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol. 140:360–367. 2005. View Article : Google Scholar : PubMed/NCBI
9	Han GM, O'Neil-Andersen NJ, Zurier RB and Lawrence DA: CD4+CD25high T cell numbers are enriched in the peripheral blood of patients with rheumatoid arthritis. Cell Immunol. 253:92–101. 2008. View Article : Google Scholar : PubMed/NCBI
10	Sansom DM and Walker LS: The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol Rev. 212:131–148. 2006. View Article : Google Scholar : PubMed/NCBI
11	Okamura T, Fujio K, Sumitomo S and Yamamoto K: Roles of LAG3 and EGR2 in regulatory T cells. Ann Rheum Dis. 2 Suppl 71:i96–i100. 2012. View Article : Google Scholar
12	Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS and Vignali DA: The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 450:566–569. 2007. View Article : Google Scholar : PubMed/NCBI
13	Wang RX, Yu CR, Dambuza IM, Mahdi RM, Dolinska MB, Sergeev YV, Wingfield PT, Kim SH and Egwuagu CE: Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med. 20:633–641. 2014. View Article : Google Scholar : PubMed/NCBI
14	Shen P, Roch T, Lampropoulou V, O'Connor RA, Stervbo U, Hilgenberg E, Ries S, Dang VD, Jaimes Y, Daridon C, et al: IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature. 507:366–370. 2014. View Article : Google Scholar : PubMed/NCBI
15	Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, Finkelstein D, Forbes K, Workman CJ, Brown SA, et al: IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol. 11:1093–1101. 2010. View Article : Google Scholar : PubMed/NCBI
16	Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB and Liew FY: IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol. 37:3021–3029. 2007. View Article : Google Scholar : PubMed/NCBI
17	Kochetkova I, Golden S, Holderness K, Callis G and Pascual DW: IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol. 184:7144–7153. 2010. View Article : Google Scholar : PubMed/NCBI
18	Ning X, Jian Z and Wang W: Low serum levels of interleukin 35 in patients with rheumatoid arthritis. Tohoku J Exp Med. 237:77–82. 2015. View Article : Google Scholar : PubMed/NCBI
19	Nakano S, Morimoto S, Suzuki S, Tsushima H, Yamanaka K, Sekigawa I and Takasaki Y: Immunoregulatory role of IL-35 in T cells of patients with rheumatoid arthritis. Rheumatology (Oxford). 54:1498–1506. 2015. View Article : Google Scholar : PubMed/NCBI
20	Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH and Luthra HS: The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:315–324. 1988. View Article : Google Scholar : PubMed/NCBI
21	Prevoo ML, van'tHof MA, Kuper HH, van Leewen MA, van de Putte LB and van Riel PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38:44–48. 1995. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Hartigan-O'Connor DJ, Poon C, Sinclair E and McCune JM: Human CD4+ regulatory T cells express lower levels of the IL-7 receptor α chain (CD127), allowing consistent identification and sorting of live cells. J Immunol Methods. 319:41–52. 2007. View Article : Google Scholar : PubMed/NCBI
24	Kawashiri SY, Kawakami A, Okada A, Koga T, Tamai M, Yamasaki S, Nakamura H, Origuchi T, Ida H and Eguchi K: CD4+CD25(high)CD127(low/-) Treg cell frequency from peripheral blood correlates with disease activity in patients with rheumatoid arthritis. J Rheumatol. 38:2517–2521. 2011. View Article : Google Scholar : PubMed/NCBI
25	Moradi B, Schnatzer P, Hagmann S, Rosshirt N, Gotterbarm T, Kretzer JP, Thomsen M, Lorenz HM, Zeifang F and Tretter T: CD4+CD25+/highCD127low/- regulatory T cells are enriched in rheumatoid arthritis and osteoarthritis joints-analysis of frequency and phenotype in synovial membrane, synovial fluid and peripheral blood. Arthritis Res Ther. 16:R972014. View Article : Google Scholar : PubMed/NCBI
26	Haque R, Lei F, Xiong X, Bian Y, Zhao B, Wu Y and Song J: Programming of regulatory T cells from pluripotent stem cells and prevention of autoimmunity. J Immunol. 189:1228–1236. 2012. View Article : Google Scholar : PubMed/NCBI
27	Wright GP, Notley CA, Xue SA, Bendle GM, Holler A, Schumacher TN, Ehrenstein MR and Stauss HJ: Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc Natl Acad Sci USA. 106:19078–19083. 2009. View Article : Google Scholar : PubMed/NCBI
28	Pope RM and Shahrara S: Possible roles of IL-12-family cytokines in rheumatoid arthritis. Nat Rev Rheumatol. 9:252–256. 2013. View Article : Google Scholar : PubMed/NCBI
29	Thiolat A, Denys A, Petit M, Biton J, Lemeiter D, Herve R, Lutomski D, Boissier MC and Bessis N: Interleukin-35 gene therapy exacerbates experimental rheumatoid arthritis in mice. Cytokine. 69:87–93. 2014. View Article : Google Scholar : PubMed/NCBI
30	Ouyang H, Shi YB, Liu ZC, Wang Z, Feng S, Kong SM and Lu Y: Decreased interleukin 35 and CD4+EBI3+ T cells in patients with active systemic lupus erythematosus. Am J Med Sci. 348:156–161. 2014. View Article : Google Scholar : PubMed/NCBI
31	Jafarzadeh A, Jamali M, Mahdavi R, Ebrahimi HA, Hajghani H, Khosravimashizi A, Nemati M, Najafipour H, Sheikhi A, Mohammadi MM and Daneshvar H: Circulating levels of interleukin-35 in patients with multiple sclerosis: Evaluation of the influences of FOXP3 gene polymorphism and treatment program. J Mol Neurosci. 55:891–897. 2015. View Article : Google Scholar : PubMed/NCBI
32	Tao L, Zhu J, Chen Y, Wang Q, Pan Y, Yu Q, Zhou B and Zhu H: IL-35 improves Treg-mediated immune suppression in atherosclerotic mice. Exp Ther Med. 12:2469–2476. 2016. View Article : Google Scholar : PubMed/NCBI
33	Zongyi Y, Funian Z, Hao L, Xin W, Ying C, Jialin Z, Yongfeng L and Baifeng L: Interleukin-35 mitigates the function of murine transplanted islet cells via regulation of Treg/Th17 ratio. PLoS One. 12:e01896172017. View Article : Google Scholar : PubMed/NCBI